id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2022-E-2196-0007,FDA,FDA-2022-E-2196,Letter to U.S. Patent and Trademark Office,Other,Letter(s),2025-01-16T05:00:00Z,2025,1,2025-01-16T05:00:00Z,,2025-01-16T21:08:03Z,,0,0,09000064868c50d7
FDA-2022-E-2196-0006,FDA,FDA-2022-E-2196,Letter from FDA CDER to U. S. Patent and Trademark Office,Other,Letter(s),2024-01-18T05:00:00Z,2024,1,2024-01-18T05:00:00Z,,2024-01-18T21:42:08Z,,0,0,09000064863a970f
FDA-2022-E-2196-0005,FDA,FDA-2022-E-2196,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2024-01-10T05:00:00Z,2024,1,2024-01-10T05:00:00Z,,2025-01-16T12:54:05Z,,0,0,090000648638ab16
FDA-2022-E-2196-0004,FDA,FDA-2022-E-2196,Determination of Regulatory Review Period for Purposes of Patent Extension; Tivdak,Notice,Determinations,2023-12-08T05:00:00Z,2023,12,2023-12-08T05:00:00Z,2024-02-07T04:59:59Z,2023-12-08T15:35:41Z,2023-26992,0,0,090000648631751d
FDA-2022-E-2196-0003,FDA,FDA-2022-E-2196,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2022-09-22T04:00:00Z,2022,9,2022-09-22T04:00:00Z,,2022-09-22T15:25:12Z,,0,0,09000064853502ab
FDA-2022-E-2196-0002,FDA,FDA-2022-E-2196,Patent Extension Application from Morrison & Foerster LLP,Other,Application,2022-09-12T04:00:00Z,2022,9,2022-09-12T04:00:00Z,,2022-09-12T15:04:39Z,,0,0,09000064852e9fa7
FDA-2022-E-2196-0001,FDA,FDA-2022-E-2196,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2022-09-12T04:00:00Z,2022,9,2022-09-12T04:00:00Z,,2022-09-12T15:04:28Z,,0,0,09000064852e9fa5